趋化因子CCL2在胶质瘤恶性进程中作用机制的研究进展  

Progress on the mechanism of chemokine CCL2 in the malignant progression of glioma

作　　者：宁义杰 胡奕奕 陈勇全 段虎斌[1] 王宏勤 Ning Yijie;Hu Yiyi;Chen Yongquan;Duan Hubin;Wang Hongqin(Department of Neurosurgery,the First Hospital of Shanxi Medical University,Taiyuan 030001,China;Department of Nuclear Medicine,the First Hospital of Shanxi Medical University,Taiyuan 030001,China;Department of Urology,the First Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第一医院神经外科,太原030001 [2]山西医科大学第一医院核医学科,太原030001 [3]山西医科大学第一医院泌尿外科,太原030001

出　　处：《肿瘤研究与临床》2022年第11期869-872,共4页Cancer Research and Clinic

基　　金：国家自然科学基金青年基金(30600637);山西省基础研究计划-面上项目(20210302124399);山西省留学人员科技活动择优资助项目(晋人社厅函[2021]479、20210020)。

摘　　要：胶质瘤是最常见的原发性颅内肿瘤,现阶段常规治疗方法效果有限,无法显著延长患者生存期。趋化因子CCL2是最重要的CC趋化因子家族成员,具有调控胶质瘤血管生成、免疫抑制、进展与侵袭、抵抗凋亡等多种功能。文章综述了CCL2促进胶质瘤恶性进程的潜在机制,旨在为胶质瘤靶向治疗提供新的思路与方法。Glioma is the most common primary intracranial tumor.At present,the conventional treatment methods have limited effect and cannot significantly prolong the survival time of patients.Chemokine CCL2 is the most important member of the CC chemokine family,which can regulate glioma angiogenesis,immunosuppression,progression and invasion,and resistance to apoptosis.This article reviews the potential mechanism of CCL2 promoting the malignant progression of glioma,in order to provide new ideas and methods for the targeted therapy of glioma.

关 键 词：神经胶质瘤 趋化因子CCL2 生物标志物 作用机制 

分 类 号：R739.41[医药卫生—肿瘤]